U.S. markets closed
  • S&P 500

    4,482.73
    -50.03 (-1.10%)
     
  • Dow 30

    34,715.39
    -313.26 (-0.89%)
     
  • Nasdaq

    14,154.02
    -186.23 (-1.30%)
     
  • Russell 2000

    2,024.04
    -38.75 (-1.88%)
     
  • Crude Oil

    86.29
    -0.67 (-0.77%)
     
  • Gold

    1,839.80
    -3.40 (-0.18%)
     
  • Silver

    24.53
    +0.30 (+1.23%)
     
  • EUR/USD

    1.1316
    -0.0031 (-0.27%)
     
  • 10-Yr Bond

    1.8330
    +0.0060 (+0.33%)
     
  • GBP/USD

    1.3601
    -0.0011 (-0.08%)
     
  • USD/JPY

    114.1100
    -0.2430 (-0.21%)
     
  • BTC-USD

    41,313.08
    -624.80 (-1.49%)
     
  • CMC Crypto 200

    992.43
    -2.83 (-0.28%)
     
  • FTSE 100

    7,585.01
    -4.65 (-0.06%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

Recap: Agenus Q1 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • AGEN

Shares of Agenus (NASDAQ:AGEN) rose 3.8% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 266.67% over the past year to ($0.20), which beat the estimate of ($0.33).

Revenue of $15,128,000 less by 81.06% year over year, which beat the estimate of $12,350,000.

Looking Ahead

Agenus hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 07, 2020

View more earnings on AGEN

Webcast URL: https://www.webcaster4.com/Webcast/Page/1556/34323

Recent Stock Performance

Company's 52-week high was at $4.57

Company's 52-week low was at $1.82

Price action over last quarter: Up 7.94%

Company Profile

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.